IL‐6 is a cytokine that had been implicated in vascular inflammation.15 IL‐6 receptor blocker with tocilizumab could reduce the expression level of C reactive protein and troponin in patients with non‐ST segment elevation myocardial infarction.16 Our study showed that the frequencies of circulating Th17 cells and the levels of IL‐17, IL‐6, and IL‐23 in patients with ACS were significantly higher than those in the patients of the control group, which suggested that Th17 cell‐mediated immune response may promote the inflammatory progression of plaque destabilization and the onset of ACS. Here, IL6 is linked to myocardial infarction.